Sarepta Therapeutics

Stop sign
Biotech

Sarepta axes late-phase DMD drug over safety signal, FDA talks

The safety signal deprived Sarepta of a near-term shot at accelerated approval—and took down the biotech’s entire PPMO franchise.
Nick Paul Taylor Nov 7, 2024 7:45am
shadow crowd crowded people walking

Sarepta's next DMD drug seems to get the job done in phase 2

Jan 29, 2024 10:49am
Peter Marks

FDA's Marks overrules staff drug reviewers 'with trepidation'

Jul 27, 2023 3:05pm
Graphic image of the US from space during the night with lights shining across the country

Santhera offloads North American rights for DMD med to Catalyst

Jun 20, 2023 9:53am
clock time delay cancelled month year hour

FDA needs more time for Sarepta's DMD gene therapy

May 24, 2023 8:39am
green light go go ahead advance yes streetlight

FDA advisers narrowly support Sarepta's DMD gene therapy

May 12, 2023 7:09pm